Drug
Lafuvitug clinical trials
Also written 3BNC117.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 8
Rockefeller University (5) · Frontier Biotechnologies Inc. (2) · Aarhus University Hospital (1) · University of Aarhus (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Zinlirvimab (4) · Albuvirtide (2) · Romidepsin (1) · MGN1703 (1)
Studies
Open first, then newest update. How each study uses lafuvitug is read from its arms, and is right about nine times in ten.
Testing it · 10
- 3BNC117 and 10-1074 in ART-treated IndividualsCompletedPhase 1Rockefeller UniversityNCT03526848Written as 3BNC117
- Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ARTCompletedPhase 2Aarhus University HospitalNCT03041012Written as 3BNC117
- Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIVCompletedPhase 2University of AarhusNCT03837756Written as 3BNC117 and 10-1074
- Romidepsin Plus 3BNC117 Phase 2a StudyCompletedPhase 2Rockefeller UniversityNCT02850016Written as 3BNC117
- Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected IndividualsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03571204Written as 3BNC117 and 10-1074
- Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed SubjectsStatus unknownPhase 2Frontier Biotechnologies Inc.NCT03719664Written as 3BNC117
- A Study of the Safety and Antiretroviral Activity of 3BNC117CompletedPhase 2Rockefeller UniversityNCT02588586Written as 3BNC117
- Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 InfectionStatus unknownPhase 2Frontier Biotechnologies Inc.NCT04819347Written as 3BNC117
- 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment InterruptionCompletedPhase 2Rockefeller UniversityNCT02446847Written as 3BNC117
- 3BNC117 and 10-1074 in HIV Uninfected AdultsCompletedPhase 1Rockefeller UniversityNCT02824536Written as 3BNC117
Given in every arm · 2 — lafuvitug is usual care beside what is tested
- Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)Status unknownPhase 1Luis MontanerNCT03588715Written as 3BNC117 + 10-1074
- 3BNC117 and 10-1074 in HIV-infected IndividualsCompletedPhase 1Rockefeller UniversityNCT02825797Written as 3BNC117
Codes
What other systems call lafuvitug · ClinicalTrials.gg INT016866
- UNII (FDA) IS3OH21U4JLAFUVITUGOne source FDA
- NCI Thesaurus C199008LafuvitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IS3OH21U4J | LAFUVITUG | One source FDA |
| NCI Thesaurus | C199008 | Lafuvitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.